Quantitative EEG Evidence of Cognitive Restoration in Alzheimer’s Disease Following Biophoton Generator Therapy
Author(s):
James Z Liu1,2*, Mariola A Smotrys1,2, Seth D Robinson2, Hui X Yu2, Sherry X Liu2, Devin R Liu2, and Helen Y Gu1,2
Background: Alzheimer’s disease (AD) is marked by progressive cognitive and electrophysiological decline. Existing treatments offer limited symptomatic
relief without reversing underlying pathology. Recent advances in biophoton therapy offer a novel, non-invasive strategy targeting mitochondrial and
neural function.Objective: To evaluate the neurophysiological and cognitive effects of biophoton generator therapy in AD patients using quantitative EEG (qEEG) metrics.Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted in 24 AD patients but 4 with serial EEG recordings were analyzed and reported in this article. Participants received nightly exposure to four strong biophoton generators for 2 to 4 weeks. Key EEG biomarkers assessed included posterior peak alpha frequency, theta/beta ratio, frontal alpha asymmetry, and P300 event-related potentials.Results:Results: Placebo-phase data showed negligible EEG changes. In contrast, 2 to 4 weeks of active treatment led to increased alpha and beta power, reduced
delta/theta activity, improved interhemispheric coherence, elevated EEG entropy, and enhanced P300 amplitude with shorter latency. Improvements were
consistent across spectral, topographic, and ERP domains, suggesting cognitive restoration and neural plasticity.Conclusion: Strong biophoton generator therapy significantly improved qEEG biomarkers in AD patients within a short treatment window. These findings
support further investigation into biophoton therapy as a safe, scalable intervention for neurodegenerative disorders.
